By Chris Wack
Boston Scientific Corp. said Tuesday it expects fourth-quarter sales to be $2.71 billion, a decline of 6.8% on a reported basis and 8% on an organic basis, compared with the prior-year period.
Analysts polled by FactSet are looking for fourth-quarter sales of $2.86 billion.
The medical technology company said quarterly results were hit by a negative 370-basis-point impact associated with the conversion of U.S. Watchman customers to a consignment inventory model and transition to the next-generation Watchman FLX Left Atrial Appendage Closure Device.
For the full year 2020, the company expects to have generated sales of $9.91 billion, a decline of 7.7% on a reported basis. Analysts are expecting sales of $10.07 billion.
Boston Scientific shares were down 5% to $34.50 in premarket trading.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
01-12-21 0707ET